LIM2 and SIGLEC10 antisense RNA 1 (LIM2-AS1)

LIM2 and SIGLEC10 antisense RNA 1 (LIM2-AS1) is annotated as an antisense long non-coding RNA gene. It is likely transcribed from the opposite strand at or near the LIM2 and SIGLEC10 loci, but there is currently no peer-reviewed literature describing its specific biological functions, molecular partners, associated disease roles, or therapeutic relevance. Antisense lncRNAs in general can regulate the transcription and/or stability of sense transcripts through RNA–RNA interactions or chromatin remodeling, but such roles for LIM2-AS1 have not been documented[4][7]. There are no known biomarkers, drugs, or safety considerations for this target. Notes on correctness and characterization: - No evidence was found that LIM2-AS1 is a *therapeutic target*, receptor, or enzyme. It is annotated only as a noncoding RNA gene[4][7]. - Information on biological function, disease involvement, and mechanisms of action is lacking, suggesting this may be a predicted or poorly characterized gene locus. - This name appears correctly formatted according to major genomic databases but does **not correspond to a protein target or receptor** by current scientific standards[4]. - If more context or functional relevance is needed, consider targeting better-characterized antisense lncRNAs such as those regulating cancer driver genes[3][5]. Summary: LIM2-AS1 is an antisense long non-coding RNA (lncRNA), not a recognized therapeutic target or receptor, and lacks characterization regarding function, disease roles, drug interactions, or use as a biomarker[4][7].

Other names

LIM2-AS1